Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.10.19
Views: 1569

Prof Eric Van Cutsem and Dr Teresa Macarulla

Prof Eric Van Cutsem (University of Leuven, Leuven, Belgium) and Dr Teresa Macarulla (Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain) discuss the latest updates presented at ESMO 2019 in pancreatic cancer.

Prof Van Cutsem and Dr Macarulla discuss the recent advances in the neoadjuvant and adjuvant setting, including recent data from the APACT and NEOLAP studies.

Dr Macarulla provides an overview of the POLO trial and reveals that quality of life is maintained during maintenance treatment with olaparib.

The experts conclude by sharing their experiences when examining tumour resectability and the importance of collaboration across disciplines when treating local disease.

This programme has been supported by an unrestricted educational grant from AstraZeneca.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation